Passage BIO, Inc. (PASG) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7027122099
Passage BIO, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -49.30 m USD |
| EBIT | -45.52 m USD |
| Net income | -45.52 m USD |
| Diluted EPS – continuing operations | -14.35 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Passage BIO, Inc.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
More stocks
- Bolt Biotherapeutics, Inc. (BOLT)
- Greenpro Capital Corp. (GRNQ)
- FTC Solar, Inc. (FTCI)
- FULL HOUSE RESORTS INC (FLL)
- KEY TRONIC CORP (KTCC)
- Pluri Inc. (PLUR)
- American Strategic Investment Co. (NYC)
- EON Resources Inc. (EONR)
- ACCESS Newswire Inc. (ACCS)
- Foreveren (FOR.WA)
- TerraVolt Holdings, Inc. (GEDC)
- Aligos Therapeutics, Inc. (ALGS)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.